AdBio Partners
AdBio partners, founded in 2016 and based in Paris, France, is a venture capital firm specializing in early-stage investments in promising life sciences startups across Europe. It focuses on building pioneering healthcare companies by partnering closely with scientific founders and academic institutions, providing both capital and entrepreneurial support.
Key facts
Recent exits
Coverage notes
2 funds tracked, 27 portfolio companies (24 active · 3 realized). Verified weekly from public filings and deal announcements.
Funds & portfolio
Every fund AdBio Partners has raised, with its portfolio companies. Hand-checked from public filings.
AFB Fund IVC2021 · 5yr€86M16 active · 1 realized
Unrealized
16 held| Company | Sector | Geo | Entry |
|---|---|---|---|
| AndzonBio1 | Healthcare | France | 2024 |
| AndzonBio2 | Healthcare | France | 2025 |
| Anoat Therapeutics | Healthcare | France | 2023 |
| Astraveus | Healthcare | France | 2023 |
| Augustine Therapeutics | Healthcare | Belgium | 2019 |
| Calida Therapeutics | Healthcare | France | 2023 |
| Cephagenix | Healthcare | Denmark | 2025 |
| Depth Charge Therapeutics | Healthcare | Ireland | 2021 |
| DiogenX | Healthcare | France | 2020 |
| EvlaBio | Healthcare | Germany | 2025 |
| Integra Therapeutics | Healthcare | France | 2021 |
| Kiji Therapeutics | Healthcare | France | 2023 |
| Orikine Bio | Healthcare | Spain | 2026 |
| Ribonexus | Healthcare | France | 2021 |
| Tenpoint Therapeutics | Healthcare | United Kingdom | 2023 |
| Thabor Therapeutics | Healthcare | France | 2021 |
AFB Seed-FundVC2017 · 9yr€47M8 active · 2 realized
Unrealized
8 held| Company | Sector | Geo | Entry |
|---|---|---|---|
| Alderaan Biotechnology | Healthcare | France | 2020 |
| ARTHEx Biotech | Healthcare | Spain | 2020 |
| Kalsiom | Healthcare | France | 2020 |
| SparingVision | Healthcare | France | 2019 |
| Tridek-One | Healthcare | France | 2019 |
| Urania Therapeutics | Healthcare | France | 2019 |
| Wellium | Healthcare | France | 2020 |
| Yukin Therapeutics | Healthcare | France | 2019 |
Realized
2 exits| Company | Sector | Geo | Entry | Exit | Type | Buyer | MOIC |
|---|---|---|---|---|---|---|---|
| Agomab Therapeutics | Healthcare | Belgium | 2019 | 2026 | IPO | – | |
| GAMUT Therapeutics | Biotech | France | 2020 | 2021 | Trade Sale | – |
Saved GPs appear in your watchlist, one click from your workspace.
About AdBio Partners
AdBio partners is a French venture capital firm with €133 million of assets under management, founded in 2016 and headquartered in Paris. The firm specialises in early-stage investments in promising life sciences startups across Europe, focusing on building pioneering healthcare companies by partnering closely with scientific founders and management teams.
Investment thesis
AdBio Partners targets European life sciences startups at seed and Series A-B stages, with sector focus on biotech (drug discovery and development), MedTech and selective HealthTech verticals. Equity ticket sizes typically range from €1 million seed positions through to €10 million Series A-B follow-on commitments. The life sciences-exclusive mandate enables deep scientific and clinical expertise across portfolio companies, distinguishing AdBio from generalist VC peers.
Recent activity
Recent realised exits include Agomab Therapeutics (healthcare, 2026) and Univercells (biotech, 2024), reflecting active distribution across the life sciences portfolio. The platform tracks 2 funds, 20 active portfolio companies and 2 realised exits across the multi-vintage European life sciences programme. Detailed buyer names and multiple data available on Pro at €29/month.
Similar firms
Other private equity firms tracked on GP Intel.
France·€196.0BFrance·€13.2BFrance·€6.7BFrance·€4.3BFrance·€4.0BFrance·€4.0BFrance·€3.0BFrance·€2.8BFrance·€2.6BFrance·€2.5BFrance·€2.1BFrance·€2.0B